Table 3. Logistic regression analysis of factors predictive of dysglycaemia in the 2015 cohort.
| Adjusted Odds Ratio (95% CI) | ||||||
|---|---|---|---|---|---|---|
|
Model 1: Modifiable Factors (n = 336) |
Factor p-value |
Model 2: Fixed Factors (n = 294) |
Factor p-value |
Model 3: All Factors (n = 293) |
Factor p-value |
|
| Physical Activity a (hours) | 0.91 (0.82–1.00) |
0.042 | ||||
| Hypertension b | 2.92 (1.66–5.16) |
<0.001 | 2.58 (1.37–4.88) |
0.003 | ||
| Hepatic Steatosis b | 6.74 (3.48–13.03) |
<0.001 | 7.28 (3.46–15.34) |
<0.001 | ||
| HDL: Triglyceride Ratio a (mmol/l) | 1.56 (1.22–1.99) |
<0.001 | 1.73 (1.32–2.27) |
<0.001 | ||
| % Weight Gain after ARVs a | 1.07 (1.04–1.11) |
<0.001 | 1.06 (1.02–1.10) |
0.003 | ||
| Age a (years) | 1.06 (1.03–1.09) |
<0.001 | 1.07 (1.03–1.10) |
<0.001 | ||
| Duration of HIV Infection a (years) | 1.06 (1.02–1.10) |
0.003 | ||||
Collinearity was observed between the variables waist and BMI (Pearson correlation 0.851) and between HIV Duration and CD4 Nadir (Pearson correlation 0.365), and the latter of each pair was excluded from regression modelling.
Continuous variables:
a; binary variables:
bModel Chi-square values: Model 1, 107.21 (p<0.001); model 2, 53.14 (p<0.001); model 3, 121.69 (p<0.001).
In Models 2 and 3 reduced participant numbers are due to exclusion of those who were not treated with ARVs or who had not yet received 12 month’s ARV treatment in order to calculate percentage weight gain in that time.